Amt.jpg

α-Methyltryptamine is a long-lasting euphoric stimulant and a psychedelic, a research chemical which was first discovered in the 60s.

History

It was originally developed in the USA in the 60s by the Upjohn company during research into anti-depressants, and the alpha-ethylated homologue became available as a commercial anti-depressant in the US (under the name Monase). However, αMT itself was available during the 60s for use as an anti-depressant in 5 and 10mg doses in the Soviet Union, sold under the brand name Indopan.

As with many research chemicals it was examined by Alexander Shulgin and details of its effects and synthesis were described in the book TiHKAL. Both during his own experiences noted in the entry, and in his further notes drawing from the experiences of others he concludes that the chemical seems to have a wide variation in many of its properties between users and even individual experiences - particularly in effects and onset.

It was one of the first 'research chemicals' which became widely available on the Internet during the 1990s, and as a result became illegal in the USA in 2003. The drug remained relatively obscure up until this point, though it was used in certain psychotherapeutic studies during the 60s, and there are some reports which suspect recreational use took place as early as the 1960s, as a result of the chemical supply for these studies being diverged.

With the rising popularity of research chemical use on the Internet during the 21st century, it has seen increasing levels of use - and while it remains legal in most countries in the world recent efforts have been made by certain governments to illegalise it.

Dosage

none
Light 15-25mg
Common 25-40mg
Strong 40-60mg
Heavy 60mg+

Dosages from TripSit Factsheets

Duration

Note: Duration can be significantly longer with higher doses.

Oral
Onset 30-120 minutes
Total 10-16 hours

Effects

Positive

  • Increase in energy (stimulation)
  • Mood lift, smiling
  • Visual patterning and closed eye visuals
  • Increased awareness & appreciation of music
  • Empathogenic qualities

Neutral

  • General change in consciousness (as with most psychoactives)
  • Blurred vision
  • Restlessness
  • Yawning
  • Dilated pupils
  • Decreased appetite
  • Dry mouth, overstimulated taste, and resulting difficulty eating
  • Extreme, vision-obscuring visuals at high doses : "obnoxiously visual"

Negative

  • Anxiety, tension
  • Nausea and vomiting
  • Decrease in coordination
  • Muscle aching
  • Headaches
  • Jaw clenching (trisma)
  • Extreme confusion at high doses

Harm Reduction

As a stimulating psychedelic, it carries a heavy body load, and care must be taken to observe physical side-effects such as vasoconstriction, which increase rapidly with dose. Toxic effects have been described at larger doses, so care must be taken to dose accurately.

Many users report experiencing particular nausea when ingesting the drug, which is abated after vomiting. If you feel the need to vomit, do not fight it.

Avoid other MAOIs.

See Psychedelic Harm Reduction for general information.

Chemistry and Pharmacology

αMT acts as a relatively balanced reuptake inhibitor and releasing agent of the main three monoamines; serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being., norepinephrine, and dopamineA neurotransmitter associated with movement, attention, learning, and the brain’s pleasure and reward system., and as a non-selective serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. receptor agonistA substance that initiates a physiological response when combined with a receptor..

αMT is a reversible MAOIMonoamine oxidase inhibitor are drugs that inhibit the action of monoamine oxidase in the brain and so allow monoamines to accumulate. in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibition), can cause SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Syndrome when combined with monoamine releasers, SSRIs or other MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibitors.

Legal Status

αMT is scheduled in the US, Australia, Austria, Denmark, Germany, Greece,

Hungary, Japan, Lithuania, Russia, Slovakia, Slovenia, Spain, Sweden and soon in the UK as well.

Links

Top Contributors